Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Romualdo Barroso-Sousa

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Current Treatment Options in Oncology|June 20, 2020
Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to GoRomualdo Barroso-Sousa, Sara M Tolaney
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 5, 2021
Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and BeyondRomualdo Barroso-Sousa, Sara M Tolaney
Expert Review of Anticancer Therapy|September 15, 2020
Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacyRomualdo Barroso-Sousa, Sara M Tolaney
Current Oncology Reports|December 1, 2018
Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 InhibitorsRomualdo Barroso-Sousa, Patrick A Ott
Therapeutic Advances in Medical Oncology|August 3, 2016
Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implicationsRomualdo Barroso-Sousa, Otto Metzger-Filho
Cancer|October 7, 2018
Optimal treatment of early stage HER2-positive breast cancerSonia Pernas, Romualdo Barroso-Sousa, Sara M Tolaney
Future Oncology (London, England)|March 29, 2018
De-escalating treatment in the adjuvant setting in HER2-positive breast cancerRomualdo Barroso-Sousa, Pedro Exman, Sara M Tolaney
Oncotargets and Therapy|July 16, 2019
Evidence to date: talazoparib in the treatment of breast cancerPedro Exman, Romualdo Barroso-Sousa, Sara M Tolaney
Breast Care (Basel, Switzerland)|August 6, 2016
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast CancerRomualdo Barroso-Sousa, Geoffrey I Shapiro, Sara M Tolaney
Cancers|August 12, 2023
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and OpportunitiesRomualdo Barroso-Sousa, Jana Priscila Pacífico, Sarah Sammons, et al.
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Current Treatment Options in Oncology|June 20, 2020
Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to GoRomualdo Barroso-Sousa, Sara M Tolaney
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 5, 2021
Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and BeyondRomualdo Barroso-Sousa, Sara M Tolaney
Expert Review of Anticancer Therapy|September 15, 2020
Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacyRomualdo Barroso-Sousa, Sara M Tolaney
Current Oncology Reports|December 1, 2018
Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 InhibitorsRomualdo Barroso-Sousa, Patrick A Ott
Therapeutic Advances in Medical Oncology|August 3, 2016
Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implicationsRomualdo Barroso-Sousa, Otto Metzger-Filho
Cancer|October 7, 2018
Optimal treatment of early stage HER2-positive breast cancerSonia Pernas, Romualdo Barroso-Sousa, Sara M Tolaney
Future Oncology (London, England)|March 29, 2018
De-escalating treatment in the adjuvant setting in HER2-positive breast cancerRomualdo Barroso-Sousa, Pedro Exman, Sara M Tolaney
Oncotargets and Therapy|July 16, 2019
Evidence to date: talazoparib in the treatment of breast cancerPedro Exman, Romualdo Barroso-Sousa, Sara M Tolaney
Breast Care (Basel, Switzerland)|August 6, 2016
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast CancerRomualdo Barroso-Sousa, Geoffrey I Shapiro, Sara M Tolaney
Cancers|August 12, 2023
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and OpportunitiesRomualdo Barroso-Sousa, Jana Priscila Pacífico, Sarah Sammons, et al.
Pageof 10